Sangamo Therapeutics (SGMO) in Focus: Stock Moves 13.6% Higher
Sangamo Therapeutics, Inc. SGMO was a big mover last session, as the company saw its shares rise nearly 14% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $11.60 to $14.50 in the past one-month time frame.
The move came after the company reported that its Hunter syndrome treatment witnessed a new mileage when the first patient had been dosed in a phase 1/2 trial to evaluate the potential for its gene-editing technology.
Though the company has seen one positive estimate revision over the past few weeks, the Zacks Consensus Estimate for the current quarter remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Sangamo Therapeutics currently has a Zacks Rank #2 (Buy) while its Earnings ESP is positive.
Another stock worth considering in the Medical – Biomedical and Genetics industry is Myriad Genetics, Inc. MYGN which carries a Zacks Rank #1 (Strong Buy).You can see the complete list of today’s Zacks #1 Rank stocks here.
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks’ private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Myriad Genetics, Inc. (MYGN): Free Stock Analysis Report
Sangamo Therapeutics, Inc. (SGMO): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research